Enalapril Maleate Tablets, 20 mg recall — JB Chemicals And Pharmaceuticals Ltd (Class II)

JB Chemicals And Pharmaceuticals Ltd is recorded by the U.S. Food and Drug Administration (FDA) as recalling Enalapril Maleate Tablets, 20 mg — a Class II recall, initiated 2026-04-23 and posted to the FDA enforcement report on 2026-05-13, under recall number D-0520-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Failed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test”. From the product description, the form is tablets, the strength given is 20 mg, the package is described as 1,000-count bottle and it is marked Rx only. 1 National Drug Code number is printed in the record: 64980-688-10. Distribution is recorded as “Nationwide in the USA” — Nationwide (US), with the recalling firm on record in India. It is the only recall number the FDA has filed under event ID 98794. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0520-2026
FDA event ID 98794
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm JB Chemicals And Pharmaceuticals Ltd
Recall initiated 2026-04-23
Reported by FDA 2026-05-13
Report lag 20 days from initiation to report
Distribution Nationwide in the USA — Nationwide (US)
Firm location on record India
Product description (source) Enalapril Maleate Tablets, USP, 20 mg, 1,000-count bottle, Rx only, Manufactured by: Unique Pharmaceutical Laboratories (A Div. of J.B. Chemicals & Pharmaceuticals Ltd.), Mumbai 400 030, India, Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 64980-688-10.

Reason reported by FDA

Failed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test

11 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

7 identifying values matched by exact pattern in the 39-word product description above; each is a literal substring of it.

Product named Enalapril Maleate Tablets
Form Tablets
Strength 20 mg
Package 1,000-count bottle
NDC 64980-688-10
Marketing category Rx only
Manufactured by Unique Pharmaceutical Laboratories (A Div. of J.B. Chemicals & Pharmaceuticals Ltd.), Mumbai 400 030
Distributed by Rising Pharma Holdings, Inc.

Other indexed recalls from JB Chemicals And Pharmaceuticals Ltd

2 indexed records name JB Chemicals And Pharmaceuticals Ltd as the recalling firm, across 2 FDA events, reported 2026-05-13 to 2026-07-29. A coverage-limited activity count over the ingested window, not a quality rating.

Recall recordRecall numberFDA tierStrength / formReported
Cetirizine Hydrochloride Tablets USP 5 mgD-0732-2026Class I5 mg · Tablets2026-07-29

Other Class II recalls with India on record

27 indexed records carry India as the recalling firm's country, against a dataset that is predominantly United States. These are the ones that also share this recall's FDA tier.

Recall recordRecall numberRecalling firmStrength / formReported
Methohexital Sodium for Injection, 500 mgD-0662-2026Onesource Specialty Pharma Ltd500 mg · for Injection2026-07-15
Pemetrexed for Injection 100mg/VialD-0671-2026Reliance Life Sciences Private Ltd100mg/Vial · for Injection2026-07-15
Pemetrexed for Injection 500mg/VialD-0672-2026Reliance Life Sciences Private Ltd500mg/Vial · for Injection2026-07-15
Bortezomib for Injection 3.5mg/VialD-0673-2026Reliance Life Sciences Private Ltd3.5mg/Vial · for Injection2026-07-15
Azacitidine for Injection 100mg/VialD-0674-2026Reliance Life Sciences Private Ltd100mg/Vial · for Injection2026-07-15
Clomiphene Citrate USP Active Pharmaceutical Ingredient (CAS : 50-41-9), 1 KGD-0691-2026Shimoga Chemicals1 KG2026-07-15

Reported in the same month (2026-05)

48 enforcement reports carry a report date in 2026-05; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
DELFLEX, 1.5%D-0512-2026Fresenius Medical Care Holdings, Inc.Class II2026-05-13
DELFLEX, 2.5%D-0513-2026Fresenius Medical Care Holdings, Inc.Class II2026-05-13
Duloxetine Delayed-Release Capsules, 30 mgD-0514-2026Ajanta Pharma Ltd.Class II2026-05-13
Duloxetine Delayed-Release Capsules, 60 mgD-0515-2026Ajanta Pharma Ltd.Class II2026-05-13
Duloxetine Delayed-Release Capsules, 20 mgD-0516-2026Ajanta Pharma Ltd.Class II2026-05-13
BD PurPrep, 8.3%D-0517-2026Carefusion 213, LLCClass II2026-05-13
BD PurPrep, 8.3%D-0518-2026Carefusion 213, LLCClass II2026-05-13
Octreotide Acetate for Injectable Suspension, 30 mgD-0519-2026Teva Pharmaceuticals Usa, IncClass II2026-05-13

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 1 nearest to 2026-05-13 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Duloxetine Delayed-Release Capsules USP, 60mgD-0522-2026Breckenridge Pharmaceutical, Inc.60mg · Delayed-Release Capsules2026-05-13

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 64980-688-10 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); JB Chemicals And Pharmaceuticals Ltd (2 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0520-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0520-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-05-13
Ingested
2026-08-22
Record hash
6418b6c8a8d0b855

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.